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Abstract
Suppressor of cytokine signalling 3 (SOCS3) is a potent inhibitor of pro-inflammatory pathways involved in
atherogenesis and the development of neo-intimal hyperplasia (NIH), which contributes to the in-stent re-stenosis
responsible for the failure of percutaneous coronary intervention (PCI) procedures. We have shown that cyclic AMP
sensor EPAC1 triggers induction of the SOCS3 gene in vascular endothelial cells (VECs), thereby attenuating
interleukin 6 (IL-6)-mediated pro-inflammatory signalling. We propose that EPAC1 localisation to the nuclear pore
controls cyclic AMP-mediated activation of a C/EBPβ/c-Jun transcriptional complex, leading to SOCS3 induction and
suppression of pro-inflammatory signalling. Future work in this area will involve an integrated approach to determine
the wider significance of the EPAC1-C/EBPβ/c-Jun pathway in controlling human VEC function and identify new
therapeutic targets for management of chronic inflammation in vascular settings.
Background
Atherosclerosis is a serious CVD, which arises from chronic
localised inflammation at coronary and carotid arterial branch points
[1], and remains the principle cause of death in the developed world
despite changes in lifestyle and the wide-spread use of anti-
hypertensive and lipid- lowering drugs (http://www.who.int/).
Atherogenesis involves a diet-induced propagation of pro-
inflammatory responses leading to the formation of plaques
characterised by cholesterol deposition, fibrosis, remodelling and
switching of VECs from an anti-coagulant/anti-inflammatory to a pro-
thrombotic/pro-inflammatory phenotype. If untreated, these lesions
either occlude vessels or trigger their rupture, resulting in the
formation of thrombi that cause myocardial infarction or stroke.
Surgical treatment for atherosclerosis typically involves angioplasty,
where arterial plaques are removed and a stent is introduced to
maintain blood flow. However, in approximately 25-50% of cases,
mechanical injury during angioplasty can lead to NIH, characterised
by localised inflammation and proliferation of vascular smooth muscle
cells (VSMCs), thereby precipitating stent failure and myocardial
infarction [2]. The increased inflammatory activity associated with
atherosclerosis and NIH is partially brought about by increased levels
of pro-inflammatory cytokines in the circulation, particularly IL-6
[3,4]. Sustained IL-6 production is involved in chronic, low-level
vascular inflammation that leads to neointimal thickening [5], vascular
dysfunction [6], hypertension [7] and increased risk of myocardial
infarction [3]. Indeed, IL-6 has been detected in atherosclerotic
plaques [8] and increases in IL6 in elderly patients are associated with
a two-fold increase in both cardiovascular and other causes of
mortality [9]. IL-6 affects vascular endothelial cells (VECs) by
triggering counter-productive angiogenesis, through vascular
endothelial growth factor (VEGF) production [10], and increasing the
secretion of chemokine’s, like monocyte chemo-attractive protein 1
(MCP-1) [11], that recruit monocytes to the inflamed endothelium.
Given this, there is now a clear need to understand the mechanisms
regulating the control of pro-inflammatory IL-6 signalling in VECs if
we are to devise new and effective strategies to combat atherosclerosis
and NIH.
Signalling by IL-6 occurs through the IL-6 receptor complex,
composed of an IL-6-binding α chain (IL-6Rα) and gp130, which
interacts with IL-6Rα [12]. IL-6 has been reported to exert both
inflammatory and anti-inflammatory actions [13] and a single
nucleotide polymorphism (SNP; Asp358Ala) has been identified in the
IL-6R, which reduces inflammation and the risk of developing
coronary heart disease (CHD) [14,15], although the mechanisms for
this remain to be determined [16]. It is IL-6 receptor “trans- signalling”
[17] that is thought to underlie the pro-inflammatory actions of IL-6 in
a variety of diseases, including atherosclerosis [18]. During trans-
signalling, IL-6 binds to soluble forms of IL-6R (sIL-6R) allowing
activation of gp130, even in cells that do not normally express IL-6Rα,
such as VECs [17]. Since gp130 is present on all cells, trans-signalling
therefore dramatically increases the range of cell targets for IL-6
signalling to include VECs [17]. Consequently, binding of the IL-6/
sIL-6R complex to gp130 on VECs, leads to receptor clustering and
activation of the JAK-STAT3 and ERK, MAPK and PI3K signalling
pathways. Of these, it is activated STAT3 that then homodimerises and
translocates to the nucleus, where it acts as a transcription factor for
the induction of pro-inflammatory IL-6-responsive genes, such as
MCP-1 and VEGF [11,19].
Inhibition of Vascular Inflammation by SOCS3
Clearly, regulation of pro-inflammatory IL-6 signalling is vital to
prevent chronic inflammation. Understanding the mechanisms
controlling IL-6 signalling may therefore pave the way to the
development of new strategies to combat vascular inflammation. In
this light, one important mechanism for down-regulating JAK-STAT3
signalling is via the suppressor of cytokine signalling (SOCS) family of
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proteins [20], which are often induced directly by the same JAK-STAT
pathway they inhibit, forming a classical negative feedback loop [21].
For example, SOCS3 binds to JAK-phosphorylated receptors, via the
SOCS3 SH2 domain, thereby inhibiting JAK activity and, consequently,
activation of STATs 1 and 3 [22]. SOCS3 then also targets multiple
SH2-bound proteins for proteasomal degradation [22], with proteolytic
targets including JAK2 [23]. Consistent with its role as a negative
regulator of inflammatory signalling, SOCS3 expression is localised to
atherosclerotic plaques [24,25] and SOCS3 knockdown in apoE-/-
mice increases STAT activation and inflammatory gene expression in
aorta, leading to enhanced atherogenesis [25]. Moreover, IL-6 has been
reported to promote acute and chronic inflammatory disease in the
absence of SOCS3 [26] and conditional deletion of the SOCS3 gene in
vascular endothelial cells results in pathological angiogenesis [27]. In
contrast, overexpression of SOCS3, or introduction of SOCS-derived
peptides in to cells, has been shown to suppress JAK/STAT3 signalling,
acute inflammation and the development of atherosclerosis and NIH,
effectively illustrating the important protective role of SOCS3 [28-30].
Clearly, novel treatments based on the regulation of SOCS3 levels in
cells could have value in the treatment of diseases like atherosclerosis,
where there is hyper-activation of JAK-STAT3 signalling. In this
respect, the ubiquitous second messenger, cyclic AMP, which is
synthesised in VECs in response to Gsα-coupled G-protein-coupled
receptor (GPCR) activation, plays a key role in controlling SOCS3
induction and limiting cytokine action; indeed, we have defined a role
for the cyclic AMP-activated guanine nucleotide exchange factor
(GEF), exchange protein activated by cyclic AMP (EPAC1) [31,32], as a
key mediator of SOCS3 induction [31] and a central controller of anti-
inflammatory processes in VECs [33,34]. EPAC1 mediates at least
three anti-inflammatory signalling pathways in VECs; namely, down-
regulation of IL-6- and STAT3-mediated inflammatory processes [31],
which occurs through C/EBP transcription factor-dependent
induction of the SOCS3 gene [32], limiting vascular permeability
through EPAC1-mediated activation of integrins, involved in cell
spreading and adhesion of VECs to the basement membrane [35], and
promotion of endothelial barrier function through actin [36-40] and
microtubule-dependent [41] cell-cell junction formation through
stabilisation of VE-cadherin-mediated adhesion [42]. Overall, the
involvement of EPAC1 in multiple anti-inflammatory processes in
VECs presents an effective model in which to study how distinct
cellular processes may interact to present a co-ordinated program of
“protection” against inflammatory stimuli.
Hypothesis
We must now determine the cellular actions of EPAC1 that are
linked to SOCS3 induction and inhibition of IL-6 signalling. We
propose that EPAC1 may serve as a potential target for future anti-
inflammatory drug development, with a reduced risk of side effects,
based on the following observations
• EPAC1 promotes SOCS3 induction independently of potentially
harmful JNK and ERK 1 and 2, MAP kinase signalling pathways,
which are normally triggered by changes in global cyclic AMP
(Figure 1) [43,44].
• SOCS3 induction by EPAC1 requires C/EBPβ and c-Jun
transcription factors [32,44], which directly interact with the
SOCS3 promoter and may therefore serve as a point of integration
for EPAC1-regulated signalling to enable effective SOCS3 gene
induction in VECs (Figure 2) [44].
• A key AP1 transcription factor binding site is required for EPAC1
to activate the SOCS3 promoter [44].
• C-Jun is constitutively associated with the AP1 site [44], whereas
C/EBPβ is recruited to the SOCS3 promoter following EPAC1
activation [32].
• EPAC1 is mainly associated with the nuclear compartment of
fractionated HUVECs where it co- localises with the SUMO1 E3
ligase, RanBP2 (results not shown), which was previously
identified as an EPAC1 binding protein [45,46].
• The nuclear targeting domain within EPAC1 as being within
amino acids 764-838 in the GEF domain [47]. This domain
contains two areas that are unique to EPAC1 and not found in
EPAC2. Since EPAC2 is not nuclear targeted to the same degree as
EPAC1 [45] then we predict that these areas contain the key
determinants for nuclear targeting of EPAC1.
Figure 1: MAP kinase-dependent and -independent control of
SOCS3 Gene Induction by cyclic AMP Maximal induction of the
SOCS3 gene by cyclic AMP in VECs requires input both EPAC1-
(lower panel) and MAP kinase-dependent (upper panel), with no
role for PKA [32]. Activation of AP1 and C/EBP transcription
factors by EPAC1 is sufficient to induce SOCS3 induction
independently of MAP kinase signalling (lower panel) and therefore
presents as a potential drug target
Based on these findings our hypothesis is that targeting of EPAC1 to
the nuclear pore complex regulates c-Jun and C/EBPβ transcription
factors, which control SOCS3 gene induction and suppression of pro-
inflammatory cytokine signalling in VECs (Figure 1). Ongoing work is
set to test this hypothesis and extend to identify the full range of
human genes that are also regulated by this new, protective signalling
pathway in VECs. These novel genetic foci will be associated with the
protective actions of cyclic AMP and will therefore inform future
strategies targeted at combating endothelial inflammation associated
with CVD.
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